FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Biotech Enterprise Capital Monitor – USA 11/2023”.
The Monitor is a month-to-month printed overview of enterprise capital developments within the US-Biotech sector.
As of the top of November 2023, we establish the next present VC developments within the US-Biotech sector:
- In 2023, general Biotech funding within the USA has reached USD 21,391m
- In comparison with November 2022 the financing quantity decreased by roughly 28% (29,739m vs. 21,391m)
- The highest 5 offers exceed USD 273m every, the biggest transaction amounted to USD 401m with ElevateBio
- Terremoto Biosciences has the very best transaction Quantity of USD 175m in November, adopted by Kyverna USD 152m and Cognito Therapeutics USD 129m
- ARCH Enterprise Companions (USA) is main the High 5 Buyers (by deal quantity), adopted by RA Capital Administration (USA) and OrbiMed (USA)
- As a sign oncology information the very best funding exercise
To entry the total report, please click on right here.
By Mathias Klozenbücher und Johannes Hyperlink.